BVF Partners ACIU Position
ActiveBVF Partners held their position in AC Immune SA (ACIU) in Q4 2025, holding $62.2M worth of shares across 19,822,436 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds ACIU.
There is an upcoming Phase 2 readout for Placebo in 77 days (Jun 30, 2026), making the timing of BVF's position particularly relevant.
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Full company profile →Short Interest
6.3%
8.9 days to cover
BVF Partners ACIU Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 19,822,436 | — | $62.2M |
| Q3 2025 | Held | 19,822,436 | — | $57.3M |
| Q2 2025 | Held | 19,822,436 | — | $40.2M |
| Q1 2025 | Increased | 19,822,436 | +300,000 | $37.1M |
| Q4 2024 | Held | 19,522,436 | — | $52.7M |
| Q3 2024 | Increased | 19,522,436 | +687,500 | $73.8M |
| Q2 2024 | Increased | 18,834,936 | +4,263,700 | $75.2M |
| Q1 2024 | Held | 14,571,236 | — | $43.1M |
| Q4 2023 | Increased | 14,571,236 | +7,142,857 | $72.9M |
| Q3 2023 | Held | 7,428,379 | — | $21.2M |
| Q2 2023 | Held | 7,428,379 | — | $22.0M |
| Q1 2023 | New | 7,428,379 | +7,428,379 | $17.4M |
Frequently Asked Questions
Does BVF Partners own ACIU?
Yes. As of Q4 2025, BVF Partners holds 19,822,436 shares of AC Immune SA (ACIU) valued at $62.2M. This data comes from their SEC 13F filing.
How many hedge funds own ACIU?
2 specialist biotech hedge funds currently hold ACIU, including Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy ACIU?
BVF Partners's position in ACIU was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's ACIU position increasing or decreasing?
BVF Partners held their ACIU position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ACIUCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →